“Characterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy with Baricitinib 4-mg: Results From BRAVE-AA1 and -AA2 Trials” (2025) SKIN The Journal of Cutaneous Medicine, 9(1), p. s522. doi:10.25251/skin.9.supp.522.